Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPacira BioSciences, Inc.

Pacira BioSciences, Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
36.455 USD 0.03 ( 0.07%)
Last update at 2026-11-09T15:45:00Z
VOLUME
67447
Market Cap
1398.71M
P/E
19.90

Momentum Score

…

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
36.44
Low
36.46
High
52 Week Price Range
25.33
Low
41.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Pacira BioSciences develops and commercializes non‑opioid local analgesics for postoperative pain, led by its bupivacaine liposome injectable suspension used in hospitals and surgical centers. Long‑term growth may be supported by rising demand for opioid‑sparing therapies, label expansion, and wider adoption across ambulatory and international settings, making its focused franchise potentially attractive to investors.

Key risks include heavy revenue concentration on a single flagship product, pricing and reimbursement pressure, competition from generics and alternative analgesics, and regulatory or clinical setbacks.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
36.43
Dividend Yield
-
Revenue TTM
681.75M
Revenue Per Share
14.71
Gross Profit TTM
393.23M
Debt / Equity
0.67
ROE
8.49%
Net Debt
432.75M
ROCE
4.06%
Diluted EPS TTM
1.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 13.30M 56.40M 20.09M -10.75M -0.42M
Net income 15.91M 41.98M 145.52M -11.02M -0.47M
Selling general administrative 109.52M 88.32M 74.83M 71.12M 70.16M
Selling and marketing expenses 145.00M 111.02M 118.68M 129.66M 107.11M
Gross profit 467.53M 401.28M 303.50M 314.31M 250.43M
Reconciled depreciation 91.50M 13.55M 19.91M 19.58M 13.16M
Ebit 60.02M 131.06M 46.35M 38.11M 9.92M
Ebitda 121.47M 144.62M 66.86M 43.81M 23.09M
Depreciation and amortization 61.45M 13.55M 20.51M 5.70M 13.16M
Non operating income net other - -1.77M -0.59M 2.40M 5.61M
Operating income 60.02M 131.06M 46.35M 38.11M 15.91M
Other operating expenses 595.90M 408.70M 378.13M 385.32M 319.80M
Interest expense 39.98M 31.75M 25.67M 23.63M 21.95M
Tax provision -2.61M 14.42M -125.43M 0.27M 0.05M
Interest income 4.54M 0.90M 4.63M 7.38M 6.50M
Net interest income -35.43M -30.85M -21.04M -16.25M -15.45M
Income tax expense -2.61M 14.42M -125.43M 0.27M 0.05M
Total revenue 666.82M 541.53M 420.83M 421.03M 337.28M
Total operating expenses 396.60M 268.44M 260.80M 278.60M 232.95M
Cost of revenue 199.29M 140.25M 117.33M 106.71M 86.84M
Total other income expense net -46.72M -74.66M -26.26M -48.86M -2.45M
Net income from continuing ops 15.91M 41.98M 145.52M -11.02M -0.47M
Net income applicable to common shares 15.91M 41.98M 145.52M -11.02M -0.47M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1574.39M 1681.20M 2075.35M 1274.51M 831.07M
Intangible assets 483.26M 540.55M 623.97M 96.52M 104.39M
Other current assets 21.50M 15.22M 14.77M 12.27M 10.78M
Total liab 704.26M 906.19M 1344.94M 654.83M 476.12M
Total stockholder equity 870.13M 775.01M 730.41M 619.69M 354.94M
Other current liab 64.24M 89.78M 117.86M 14.74M 18.18M
Common stock 0.05M 0.05M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.05M 0.04M 0.04M 0.04M
Retained earnings -106.80M -148.75M -211.90M -253.88M -399.40M
Other liab - 37.79M 77.57M 17.44M 21.46M
Good will 163.24M 163.24M 145.18M 99.55M 99.55M
Other assets 0.00M 160.31M 153.36M 290.13M 0.97M
Cash 153.30M 104.14M 585.58M 99.96M 78.23M
Total current liabilities 97.38M 147.77M 521.12M 253.33M 107.67M
Current deferred revenue - - 10.12M 71.09M 71.76M
Net debt 432.75M 659.25M 543.27M 441.17M 273.69M
Short term debt 17.44M 42.77M 382.59M 157.07M 4.93M
Short long term debt 8.64M 33.65M 374.70M 149.65M -
Short long term debt total 586.04M 763.39M 1128.85M 541.13M 351.92M
Other stockholder equity 976.63M 924.10M 942.09M 873.20M 753.98M
Property plant equipment - 254.39M 264.81M 136.69M 104.68M
Total current assets 509.99M 498.33M 866.05M 651.62M 408.56M
Long term investments 2.41M 64.38M 21.99M 109.48M 64.80M
Net tangible assets - 71.22M -38.73M 423.62M 151.01M
Short term investments 125.28M 184.51M 70.83M 421.70M 213.72M
Net receivables 105.56M 98.40M 96.32M 53.05M 47.53M
Long term debt 513.80M 655.82M 674.53M 313.03M 306.05M
Inventory 104.35M 96.06M 98.55M 64.65M 58.30M
Accounts payable 15.70M 15.22M 10.54M 10.43M 12.80M
Accumulated other comprehensive income 0.25M -0.38M 0.17M 0.32M 0.32M
Common stock total equity - - 0.04M 0.04M 0.04M
Retained earnings total equity - - -211.90M -253.88M -399.40M
Non currrent assets other 36.05M 27.17M 76.41M 74.49M 10.97M
Non current assets total 1064.39M 1182.87M 1209.31M 622.89M 422.51M
Capital lease obligations 63.61M 73.92M 79.62M 78.45M 45.87M
Long term debt total - - - 313.03M 306.05M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -225.19M 449.12M -239.81M 0.98M 41.93M
Change to liabilities 6.27M -10.14M -11.78M 11.66M 5.53M
Total cashflows from investing activities -225.19M -20.79M -277.61M -128.49M 20.58M
Net borrowings -427.69M 363.75M 125.43M -0.34M -0.34M
Total cash from financing activities -401.53M 380.69M 222.30M 3.67M 8.95M
Change to operating activities -23.11M -0.47M -18.61M 9.23M 2.87M
Net income 15.91M 41.98M 145.52M -11.02M -0.47M
Change in cash -481.44M 485.62M 21.73M -54.30M 78.40M
Begin period cash flow 585.58M 99.96M 78.23M 132.53M 54.13M
End period cash flow 104.14M 585.58M 99.96M 78.23M 132.53M
Total cash from operating activities 145.27M 125.72M 77.03M 70.52M 48.87M
Depreciation 91.50M 28.55M 19.91M 19.58M 13.16M
Other cashflows from investing activities - -424.04M - -119.31M -6.84M
Dividends paid - 2.67M 1.62M 4.32M -
Change to inventory 2.49M -4.47M -6.35M -8.03M -7.16M
Change to account receivables -2.08M -10.43M -5.52M -8.52M -6.00M
Sale purchase of stock 2.95M 2.81M 45.22M 8.47M 7.17M
Other cashflows from financing activities -1.18M 380.56M 433.80M 8.32M 8.95M
Change to netincome 57.59M 54.79M -75.01M 55.65M 32.64M
Capital expenditures 30.08M 45.87M 37.80M 10.16M 14.51M
Change receivables - -10.43M -5.52M -8.52M -6.00M
Cash flows other operating - -5.69M -10.15M -4.25M -3.23M
Cash and cash equivalents changes - 485.62M 21.73M -54.30M 78.40M
Change in working capital -16.43M -18.67M -24.39M -8.77M -10.86M
Stock based compensation 48.09M 42.25M 39.92M 33.65M 31.73M
Other non cash items 14.15M 20.75M 22.68M 31.75M 14.39M
Free cash flow 115.20M 79.85M 39.23M 60.36M 34.36M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PCRX
Pacira BioSciences, Inc.		 0.03
0.07%		 36.45 19.90 9.77 1.85 1.44 2.31 10.07
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Pacira BioSciences, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

5401 West Kennedy Boulevard, Tampa, FL, United States, 33609

813 553 6680

https://www.pacira.com

711

Name Title Year Born
Mr. David M. Stack Chairman & CEO 1950
Mr. Charles A. Reinhart III, CPA, M.B.A. Chief Financial Officer 1961
Dr. Roy Winston M.D. Chief Medical Officer 1962
Mr. Max Reinhardt Pres of Rest of World 1971
Dr. Jonathan Slonin M.D. Chief Clinical Officer 1975
Mr. Daryl Gaugler Chief Operating Officer 1962
Ms. Lauren Bullaro Riker Principal Accounting Officer & VP of Fin. 1979
Mr. Charles Laranjeira Chief Technical Officer 1966
Ms. Kristen Williams J.D. Chief Admin. Officer & Sec. 1974
Susan Mesco Head of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…